SI9520044B - Inhibitorji Xa faktorja - Google Patents

Inhibitorji Xa faktorja Download PDF

Info

Publication number: SI9520044B
Authority: SI; Slovenia
Prior art keywords: chg; arg; paph; leu; pro
Prior art date: 1994-04-26

Application number

SI9520044A

Other languages

English (en)

Slovenian (sl)

Other versions

SI9520044A (en

Inventor

Fahad Al-Obeidi

Michal Lebd

A. James Ostrem

Pavel Safar

Alena Stierandova

Peter Strop

Armin Wasler

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-26

Filing date

1995-04-25

Publication date

2004-08-31

1995-04-25 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

1997-10-31 Publication of SI9520044A publication Critical patent/SI9520044A/sl

2004-08-31 Publication of SI9520044B publication Critical patent/SI9520044B/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Crystallography & Structural Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

SI9520044A 1994-04-26 1995-04-25 Inhibitorji Xa faktorja SI9520044B (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23305494A	1994-04-26	1994-04-26
PCT/US1995/005268 WO1995029189A1 (en)	1994-04-26	1995-04-25	FACTOR Xa INHIBITORS

Publications (2)

Publication Number	Publication Date
SI9520044A SI9520044A (en)	1997-10-31
SI9520044B true SI9520044B (sl)	2004-08-31

Family

ID=22875692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9520044A SI9520044B (sl)	1994-04-26	1995-04-25	Inhibitorji Xa faktorja

Country Status (27)

Country	Link
EP (2)	EP0758341B1 (lt)
JP (1)	JP3655632B2 (lt)
KR (1)	KR100380124B1 (lt)
CN (1)	CN1181091C (lt)
AT (1)	ATE262536T1 (lt)
AU (1)	AU707653B2 (lt)
CA (1)	CA2186497C (lt)
CZ (1)	CZ296439B6 (lt)
DE (1)	DE69532754T2 (lt)
DK (1)	DK0758341T3 (lt)
EE (1)	EE03973B1 (lt)
ES (1)	ES2214500T3 (lt)
FI (1)	FI120494B (lt)
HU (1)	HUT76346A (lt)
IL (1)	IL113505A (lt)
LT (1)	LT4218B (lt)
LV (1)	LV11740B (lt)
NO (1)	NO318759B1 (lt)
NZ (1)	NZ284977A (lt)
PL (1)	PL188132B1 (lt)
PT (1)	PT758341E (lt)
RU (1)	RU2152954C1 (lt)
SI (1)	SI9520044B (lt)
SK (1)	SK286094B6 (lt)
TW (1)	TW409129B (lt)
WO (1)	WO1995029189A1 (lt)
ZA (1)	ZA953361B (lt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH11500120A (ja) *	1995-02-17	1999-01-06	ビーエーエスエフアクチェンゲゼルシャフト	新規なトロンビンインヒビター
US5747458A (en) *	1995-06-07	1998-05-05	Chiron Corporation	Urokinase receptor ligands
US6069130A (en)	1995-06-07	2000-05-30	Cor Therapeutics, Inc.	Ketoheterocyclic inhibitors of factor Xa
US5766932A (en) *	1995-12-20	1998-06-16	Hoechst Marion Roussel, Inc.	Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin
CN1087349C (zh) *	1995-12-20	2002-07-10	阿温蒂斯药物公司	N－乙酰基－(L)－4－氰基苯丙氨酸Ac-(L)-Phe(4－CN)－OH与N－乙酰基－(L)－对脒基苯丙氨酸－环己基甘氨酸－β－（3－N－甲基吡啶鎓）－丙氨酸AC－（L）－PAPh－chg－PaIMe(3)-NH2的新颖的制备方法
US6262047B1 (en)	1996-10-11	2001-07-17	Cor Therapeutics, Inc.	Selective factor Xa inhibitors
US6194435B1 (en)	1996-10-11	2001-02-27	Cor Therapeutics, Inc.	Lactams as selective factor Xa inhibitors
US6369080B2 (en)	1996-10-11	2002-04-09	Cor Therapeutics, Inc.	Selective factor Xa inhibitors
US6063794A (en)	1996-10-11	2000-05-16	Cor Therapeutics Inc.	Selective factor Xa inhibitors
CA2285659A1 (en)	1997-04-14	1998-10-22	Cor Therapeutics, Inc.	Selective factor xa inhibitors
WO1998046626A1 (en)	1997-04-14	1998-10-22	Cor Therapeutics, Inc.	SELECTIVE FACTOR Xa INHIBITORS
CA2285705A1 (en) *	1997-04-14	1998-10-22	Cor Therapeutics, Inc.	Selective factor xa inhibitors
US7109326B2 (en)	1997-04-15	2006-09-19	Genentech, Inc.	Halo-alkoxycarbonyl prodrugs
US6333321B1 (en)	1997-08-11	2001-12-25	Cor Therapeutics, Inc.	Selective factor Xa inhibitors
US6228854B1 (en)	1997-08-11	2001-05-08	Cor Therapeutics, Inc.	Selective factor Xa inhibitors
US6218382B1 (en)	1997-08-11	2001-04-17	Cor Therapeutics, Inc	Selective factor Xa inhibitors
GB9727123D0 (en) *	1997-12-22	1998-02-25	Int Centre Genetic Eng & Bio	Synthesis of diamines
KR100608472B1 (ko)	1997-12-24	2006-08-09	사노피-아벤티스 도이칠란트 게엠베하	인자 Ｘａ의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물
EP0987274A1 (en) *	1998-09-15	2000-03-22	Hoechst Marion Roussel Deutschland GmbH	Factor VIIa Inhibitors
EP1016663A1 (en) *	1999-01-02	2000-07-05	Aventis Pharma Deutschland GmbH	Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
EP1022268A1 (en) *	1999-01-02	2000-07-26	Aventis Pharma Deutschland GmbH	Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
ID29979A (id)	1999-01-02	2001-10-25	Aventis Pharma Gmbh	Turunan asam malonat baru, proses pembuatannya, penggunaannya dan komposisi sediaan farmasi yang mengandung bahan tersebut (penghambatan aktivitas faktor xa)
DE69924527T2 (de) *	1999-01-02	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen
EP1059302A1 (en) *	1999-06-08	2000-12-13	Aventis Pharma Deutschland GmbH	Factor VIIa inhibitors
EP1095933A1 (en)	1999-10-30	2001-05-02	Aventis Pharma Deutschland GmbH	Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
AU1890201A (en) *	1999-12-14	2001-06-25	Showa Denko Kabushiki Kaisha	Process for producing salt of cyanobenzylamine or derivative
JP5088598B2 (ja) *	1999-12-14	2012-12-05	昭和電工株式会社	シアノベンジルアミン類の塩の製造方法
SK10842002A3 (sk) *	2000-01-28	2003-04-01	Aventis Pharma Deutschland Gmbh	Spôsob prípravy acetyl-amidiniofenylalanyl-cyklohexylglycyl- pyridinioalanínamidov a medziprodukty používané pri tomto spôsobe
EP1127884A1 (en) *	2000-02-26	2001-08-29	Aventis Pharma Deutschland GmbH	Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
DE10029015A1 (de) *	2000-06-15	2001-12-20	Curacyte Ag	Hemmstoffe für den Gerinnungsfaktor Xa
JP4274522B2 (ja)	2000-12-06	2009-06-10	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｘａ因子阻害剤としてのグアニジンおよびアミジン誘導体
EP1314733A1 (en)	2001-11-22	2003-05-28	Aventis Pharma Deutschland GmbH	Indole-2-carboxamides as factor Xa inhibitors
GB0130705D0 (en) *	2001-12-21	2002-02-06	Glaxo Group Ltd	Chemical compounds
DE50310038D1 (de)	2002-03-11	2008-08-07	Curacyte Ag	Hemmstoffe der urokinase, ihre herstellung und verwendung
DK1569912T3 (en)	2002-12-03	2015-06-29	Pharmacyclics Inc	2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US7358268B2 (en)	2002-12-04	2008-04-15	Sanofi-Aventis Deutschland Gmbh	Imidazole derivatives as factor Xa inhibitors
GB0228533D0 (en) *	2002-12-06	2003-01-15	Glaxo Group Ltd	Crystalline form
US7429581B2 (en)	2002-12-23	2008-09-30	Sanofi-Aventis Deutschland Gmbh	Pyrazole-derivatives as factor Xa inhibitors
DE10301300B4 (de)	2003-01-15	2009-07-16	Curacyte Chemistry Gmbh	Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7317027B2 (en)	2003-05-19	2008-01-08	Sanofi-Aventis Deutschland Gmbh	Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en)	2003-05-19	2010-06-22	Sanofi-Aventis Deutschland Gmbh	Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en)	2003-05-19	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479677A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	New indole derivatives as factor xa inhibitors
EP1479680A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Azaindole derivatives as Factor Xa inhibitors
EP1479675A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Indazole-derivatives as factor Xa inhibitors
DE10342108A1 (de)	2003-09-11	2005-04-14	Curacyte Chemistry Gmbh	Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1568698A1 (en)	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrole-derivatives as factor Xa inhibitors
AU2005299693B2 (en)	2004-10-26	2012-07-05	Janssen Pharmaceutica, N.V.	Factor Xa compounds
EP1724269A1 (en)	2005-05-20	2006-11-22	Sanofi-Aventis Deutschland GmbH	Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
DE102005044319A1 (de)	2005-09-16	2007-03-22	Curacyte Chemistry Gmbh	2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de)	2006-10-24	2008-04-30	Curacyte Discovery Gmbh	Hemmstoffe des Plasmins und des Plasmakallikreins
EP1918718A1 (de) *	2006-10-31	2008-05-07	Roche Diagnostics GmbH	Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben
MX2009010953A (es)	2007-04-13	2009-10-29	Millenium Pharmaceuticals Inc	Terapia anticoagulante en combinacion, con un compuesto que actua como un inhibidor del factor xa.
DE102023133734A1 (de)	2023-12-01	2025-06-05	Technische Universität Darmstadt, Körperschaft des öffentlichen Rechts	Schnelle Bestimmung von Analytgehalten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275153A (en) *	1978-08-03	1981-06-23	American Hospital Supply Corporation	Analytical fluorogenic substrates for proteolytic enzymes
CA1161431A (en) *	1979-05-11	1984-01-31	Lars G. Svendsen	Tripeptide derivatives
US4469679A (en) *	1983-02-16	1984-09-04	Smithkline Beckman Corporation	Octapeptide vasopressin antagonists
HU191961B (en) *	1984-08-02	1987-04-28	Richter Gedeon Vegyeszet	Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
CA2008116C (en) *	1989-02-23	2001-11-20	Thomas Weller	Glycine derivatives
HU206372B (en) *	1990-09-03	1992-10-28	Richter Gedeon Vegyeszet	Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
EP0627929B1 (en) *	1992-02-14	1998-09-30	Corvas International, Inc.	Inhibitors of thrombosis

1995
- 1995-04-25 SI SI9520044A patent/SI9520044B/sl not_active IP Right Cessation
- 1995-04-25 PT PT95917736T patent/PT758341E/pt unknown
- 1995-04-25 DE DE69532754T patent/DE69532754T2/de not_active Expired - Lifetime
- 1995-04-25 WO PCT/US1995/005268 patent/WO1995029189A1/en not_active Ceased
- 1995-04-25 NZ NZ284977A patent/NZ284977A/en not_active IP Right Cessation
- 1995-04-25 SK SK1366-96A patent/SK286094B6/sk not_active IP Right Cessation
- 1995-04-25 CA CA002186497A patent/CA2186497C/en not_active Expired - Fee Related
- 1995-04-25 RU RU96122647/04A patent/RU2152954C1/ru not_active IP Right Cessation
- 1995-04-25 EE EE9600146A patent/EE03973B1/xx not_active IP Right Cessation
- 1995-04-25 EP EP95917736A patent/EP0758341B1/en not_active Expired - Lifetime
- 1995-04-25 HU HU9602954A patent/HUT76346A/hu not_active Application Discontinuation
- 1995-04-25 KR KR1019960706004A patent/KR100380124B1/ko not_active Expired - Fee Related
- 1995-04-25 AU AU23683/95A patent/AU707653B2/en not_active Ceased
- 1995-04-25 JP JP52785395A patent/JP3655632B2/ja not_active Expired - Fee Related
- 1995-04-25 EP EP03021617A patent/EP1384725A3/en not_active Withdrawn
- 1995-04-25 DK DK95917736T patent/DK0758341T3/da active
- 1995-04-25 AT AT95917736T patent/ATE262536T1/de not_active IP Right Cessation
- 1995-04-25 ES ES95917736T patent/ES2214500T3/es not_active Expired - Lifetime
- 1995-04-25 ZA ZA953361A patent/ZA953361B/xx unknown
- 1995-04-25 CN CNB951928112A patent/CN1181091C/zh not_active Expired - Fee Related
- 1995-04-25 CZ CZ0314096A patent/CZ296439B6/cs not_active IP Right Cessation
- 1995-04-26 IL IL11350595A patent/IL113505A/xx not_active IP Right Cessation
- 1995-05-11 TW TW084104681A patent/TW409129B/zh active
1996
- 1996-09-25 PL PL95317067A patent/PL188132B1/pl not_active IP Right Cessation
- 1996-10-25 NO NO19964553A patent/NO318759B1/no not_active IP Right Cessation
- 1996-10-25 LT LT96-151A patent/LT4218B/lt not_active IP Right Cessation
- 1996-10-25 FI FI964317A patent/FI120494B/fi not_active IP Right Cessation
- 1996-11-15 LV LVP-96-410A patent/LV11740B/en unknown

Also Published As

Publication number	Publication date
CZ296439B6 (cs)	2006-03-15
EP0758341A1 (en)	1997-02-19
CZ314096A3 (en)	1997-05-14
CN1147261A (zh)	1997-04-09
NO318759B1 (no)	2005-05-02
LV11740A (lv)	1997-04-20
IL113505A (en)	1999-12-31
IL113505A0 (en)	1995-07-31
PT758341E (pt)	2004-08-31
FI964317A7 (fi)	1996-10-25
SI9520044A (en)	1997-10-31
FI964317A0 (fi)	1996-10-25
EP1384725A3 (en)	2007-02-21
DE69532754T2 (de)	2005-03-10
PL317067A1 (en)	1997-03-03
DE69532754D1 (de)	2004-04-29
JP3655632B2 (ja)	2005-06-02
NZ284977A (en)	1998-09-24
DK0758341T3 (da)	2004-06-28
JPH10503477A (ja)	1998-03-31
AU707653B2 (en)	1999-07-15
CA2186497A1 (en)	1995-11-02
WO1995029189A1 (en)	1995-11-02
EE9600146A (et)	1997-04-15
TW409129B (en)	2000-10-21
EE03973B1 (et)	2003-02-17
NO964553L (no)	1996-12-27
SK136696A3 (en)	1997-05-07
LT4218B (en)	1997-09-25
CA2186497C (en)	2008-06-17
HU9602954D0 (en)	1996-12-30
ES2214500T3 (es)	2004-09-16
AU2368395A (en)	1995-11-16
HUT76346A (en)	1997-08-28
ATE262536T1 (de)	2004-04-15
CN1181091C (zh)	2004-12-22
SK286094B6 (sk)	2008-03-05
RU2152954C1 (ru)	2000-07-20
EP1384725A2 (en)	2004-01-28
LT96151A (en)	1997-05-26
NO964553D0 (no)	1996-10-25
FI120494B (fi)	2009-11-13
KR100380124B1 (ko)	2003-08-02
PL188132B1 (pl)	2004-12-31
ZA953361B (en)	1996-01-12
EP0758341B1 (en)	2004-03-24
LV11740B (en)	1997-12-20

Publication	Publication Date	Title
SI9520044B (sl)	2004-08-31	Inhibitorji Xa faktorja
McKleroy et al.	2013	Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis
CA2712512C (en)	2018-08-28	Use of serine protease inhibitors in the treatment of skin diseases
ES2567706T3 (es)	2016-04-26	Tetrapéptidos protectores para cuidado cutáneo
JPS60500870A (ja)	1985-06-06	酵素阻害剤
Manfro et al.	2012	Effect of different concentrations of chlorhexidine on bond strength of primary dentin
ATE276736T1 (de)	2004-10-15	Zubereitung zur verbesserung der epithelialen lipidbarrierefunktion
US20220370360A1 (en)	2022-11-24	Compositions for treating viral infections and methods for same
CN104398390B (zh)	2017-10-03	牙本质底涂‑冲洗底涂剂及其方法
CN104159599B (zh)	2017-02-01	双功能肽
Bakowska et al.	1998	Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin‐induced lung injury
EP1257582B1 (en)	2009-04-29	Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
Hiwada et al.	1988	A highly potent and long-acting oral inhibitor of human renin.
UA89684C2 (ru)	2010-02-25	Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида
JPS61263927A (ja)	1986-11-21	修飾ヒルデイン類、その製法およびこれを有効成分として含む薬用製剤
BR9908479A (pt)	2000-12-05	Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
JP3573803B2 (ja)	2004-10-06	皮膚外用剤
Taki et al.	1995	Gastrointestinal absorption of peptide drug: quantitative evaluation of the degradation and the permeation of metkephamid in rat small intestine.
Majima et al.	1993	Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine
Ingerman-Wojenski et al.	1988	Model system to study interaction of platelets with damaged arterial wall: II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719
Frankel et al.	1991	Induction of unilateral pulmonary fibrosis in the rat by cadmium chloride
WO2004060908A2 (en)	2004-07-22	Method to increase fibronectin
Zhou et al.	2013	Study on related indexes of the coagulation and fibrinolytic system after renal ischemia reperfusion injury in Wistar rats
JP2003246730A (ja)	2003-09-02	トリプターゼ阻害剤
TW199863B (lt)	1993-02-11

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2011-12-30	KO00	Lapse of patent	Effective date: 20111128